Halozyme Therapeutics, Inc. has grown revenue 29% a year over three years and 35% a year over five, with earnings per share compounding at 30%. Revenue growth, 3-year annual rate: +29% (Biotechnology median +21%). Revenue growth, 5-year rate: +35%, growth has slowed since the five-year average. Earnings per share, 3-year rate: +30%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 17, FY2009 to FY2025, as filed.

HALOHalozyme Therapeutics, Inc.

HealthcareUSD

$107.05

$61.6352 weeks$109.30

Is it growing?

Is HALO growing?

Halozyme Therapeutics, Inc. has grown revenue 29% a year over three years and 35% a year over five, with earnings per share compounding at 30%.

+29%

Revenue growth, 3-year annual rate · Biotechnology median +21% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +35%
Revenue growth, 5-year rate · +29% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: +30%
Earnings per share, 3-year rate · revenue +29% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed